- Advanced equipment and technique
- Experienced scientific team
- Highly reliable and reproducible result
- Data analysis, detailed report with results and discussion
- Quality one-stop service

Lenalidomide - CAS 191732-72-6

Inquiry

Catalog Number	Size	Price	Stock	Quantity
BP-900061	25 g	$298	In stock

Add to cart

Cereblon binder; induces ubiquitination and degradation of CK1a and transcription factors IKZF1, IKZF3 and SALL4 by E3 ubiquitin ligase

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Molecular Formula

C13H13N3O3

Molecular Weight

259.26

Lenalidomide

- Specification
  - Purity
    
    ≥98% (HPLC)
    
    Solubility
    
    DMSO:25.93mg/mL
    
    Appearance
    
    White solid powder
    
    Shelf Life
    
    >2 years if stored properly
    
    Storage
    
    Store at -20°C
    
    Shipping
    
    Room temperature in continental US; may vary elsewhere.
    
    Synonyms
    
    CC5013; CC-5013; CC 5013; IMiD1; Lenalidomide; US brand name: Revlimid
- Properties
  - Melting Point
    
    >250°C (dec.)
    
    Chemical Name
    
    3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione
    
    InChI Key
    
    InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
    
    InChI
    
    GOTYRUGSSMKFNF-UHFFFAOYSA-N
    
    Canonical SMILES
    
    NC1=C2CN(C(C2=CC=C1)=O)C3CCC(NC3=O)=O
    
    Biological Activity
    
    Thalidomide analog. Immune modulatory drug and cereblon binding compound. Induces ubiquitination and degradation of casein kinase (CK) 1α by the E3 ubiquitin ligase CRL4CRBN. Also TNF-α inhibitor and angiogenesis inhibitor. Promotes degradation of transcription factor SALL4.
- Reference Reading
  - 1.Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    
    Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Vel N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
    
    BACKGROUND: Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.
    
    2.A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.
    
    Cherian MA1, Tibes R2, Gao F3, Fletcher T1, Fiala M1, Uy GL1, Westervelt P1, Jacoby MA1, Cashen AF1, Stockerl-Goldstein K1, DiPersio JF1, Vij R1. Leuk Lymphoma. 2016 Apr 27:1-6. [Epub ahead of print]
    
    Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by bone marrow failure which frequently progress to acute myeloid leukemia. Patients who fail to respond to, or progress on first-line DNA hypomethylating agents (HMA) have a poor prognosis. Conventionally dosed lenalidomide has activity in 5q-MDS. In other subtypes, it may reduce RBC transfusion requirements but does not result in cytogenetic responses. We previously reported that high-dose lenalidomide induction (50 mg/day) results in complete remissions in a high fraction of patients. We, therefore, conducted a Phase 2 trial of the same regimen in MDS refractory to HMA. Marrow complete remissions were seen in 33% of patients and hematological improvement in 8% of patients. Significant infections complicated more than 50% of cases. Future trials to explore alternative dosing schedules of high-dose lenalidomide to increase efficacy while decreasing toxicity are warranted.

Bio Calculators

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂

Calculate

* Total Molecular Weight:

g/mol

Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳

Formula weight: *

g/mol

Desired final volume: *

Desired concentration: *